# Antengene Presents Latest Preclinical Results of Novel Cos-TCE Platform AnTenGager‑D2 in Rapid Oral Abstract Presentation at SITC 2026

- Source: PR Newswire M&A
- Published: 2026-11-09T00:30:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/antengene-presents-latest-preclinical-results-of-novel-cos-tce-platform-antengagerd2-in-rapid-oral-abstract-presentation-at-sitc-2026-302931879.html
- Canonical: https://groundlevelnews.com/story/antengene-presents-latest-preclinical-results-of-novel-cos-tce-platfor-dabc4c/

SHANGHAI and HONG KONG, Nov. 8, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._